ReviewClinical pharmacokinetics2010
Pharmacological issues of linezolid: an updated critical review.
Review in Clinical pharmacokinetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review.Critical care (London, England) · 2016Pooled it
- Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains.European journal of clinical pharmacology · 2021Trial
- Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.Clinical pharmacokinetics · 2017Trial
- Linezolid for treatment of chronic extensively drug-resistant tuberculosis.The New England journal of medicine · 2012Trial
- Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations.Microorganisms · 2026Review
- The protective role of vitamin C against linezolid-induced hepato-renal toxicity in a rat model.Frontiers in pharmacology · 2025Article
- Efficacy and Safety of Continuous vs Intermittent Linezolid Infusion in Critically Ill Patients with Septic Shock.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part II.Antibiotics (Basel, Switzerland) · 2022Review
- Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients.Frontiers in pharmacology · 2022Article
- Model Based Identification of Linezolid Exposure-toxicity Thresholds in Hospitalized Patients.Frontiers in pharmacology · 2021Article
- Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India.Journal of clinical tuberculosis and other mycobacterial diseases · 2020Article
- Lactic Acidosis and Thrombocytopenia Associated with Linezolid Therapy: A Case Report.The American journal of case reports · 2018Article
- Pharmacokinetics and pharmacodynamics of Linezolid in burn patients.Annals of burns and fire disasters · 2018Article
- Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.Antimicrobial agents and chemotherapy · 2017Article
- Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.Antimicrobial agents and chemotherapy · 2016Observational
- Pharmacokinetics of Tedizolid in Morbidly Obese and Covariate-Matched Nonobese Adults.Antimicrobial agents and chemotherapy · 2016Article
- Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring.European journal of clinical pharmacology · 2015Article
- Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis.Antimicrobial agents and chemotherapy · 2014Article
- Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study.Critical care (London, England) · 2014Observational
- Expression Profile of Markers of Apoptosis, Injury and Oxidative Stress in Human Lung Epithelium Cells-A5449 Receiving Chronic Exposure of Potential Anti-Tubercular Drug-trans-Cyclohexane-1, 4-Diamine Derivative-"9u".Toxicology international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid is the first oxazolidinone agent introduced into clinical practice for use against Gram-positive bacteria that are resistant to beta-lactams and glycopeptides, including methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). An optimal antibacterial effect is achieved when plasma drug concentrations are above the minimum inhibitory concentration (MIC) [T>MIC] for the entire length of treatment and the ratio between the area under the plasma concentration-time curve (AUC) and the MIC (AUC/MIC) is greater than 100, as is most commonly obtained with administration of the standard dosage of linezolid 600 mg twice daily. A wide tissue distribution, including the CNS and respiratory tract, nearly linear pharmacokinetics and good tolerability are additional characteristics of linezolid. However, variability in the drug pharmacokinetics associated with clinical conditions (e.g. sepsis, burn injuries, end-stage renal disease, cystic fibrosis), haemodialysis and/or young age may lower the T>MIC and the AUC/MIC ratio, thus impairing both antibacterial activity and prevention of mutants. In most cases, changes in the dosage or in the schedule of administration (e.g. an additional [third] daily dose) may improve the effectiveness of linezolid. It is worth noting that linezolid could affect its own metabolism as a result of protein synthesis inhibition in mitochondria, and this could lead to high plasma concentrations and an increased risk of non-negligible toxicities. The latter may be reported during long-term administration of linezolid or in the presence of some pathological conditions (e.g. renal disease or kidney transplantation) associated with high plasma drug concentrations. Therefore, treatment optimization should be considered a requirement for more effective and tolerable use of the drug, particularly in special populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.